What changed.

evidence: Eli Lilly's retatrutide reported topline Phase 3 TRIUMPH program results of ~28% body weight loss — described as not yet peer-reviewed. NDA submission projected Q4 2026 after TRIUMPH-2 and TRIUMPH-3 readouts complete the filing package. (PeptideNewsNetwork, 2026-07-17)

regulatory: Clarivate's Drugs to Watch 2026 report, published ~14 hours ago, named orforglipron among the defining drugs of the next decade, projecting $16B in 2031 sales; FDA review is ongoing with decision expected in 2026. (PharmExec / Clarivate, 2026-07-17)

trial_dose: ClinicalTrials.gov updated a study of tirzepatide (LY3298176) once weekly in adolescent participants with obesity or overweight with weight-related comorbidities. Listing refreshed within the last 24h per peptidebenchmark.com aggregator. (ClinicalTrials.gov, 2026-07-17)

trial_dose: ClinicalTrials.gov posted an update on a study of semaglutide delivered epi-intradermally via microarray patch (VX-201) vs. subcutaneous injection in healthy overweight/obese participants, signaling novel delivery route investigation. (ClinicalTrials.gov, 2026-07-17)

regulatory: FDA's Pharmacy Compounding Advisory Committee convenes July 23, 2026 to evaluate BPC-157, KPV, TB-500, and MOTS-C for inclusion on the 503A Bulk Drug Substances List. A positive recommendation would open a legal compounding pathway but does not constitute FDA drug approval. Public comment docket (FDA-2025-N-6895) closes July 22. (FDA.gov, 2026-07-16)

evidence: REDEFINE 1 Phase IIIa trial (NCT05567796) data published in NEJM shows once-weekly CagriSema (cagrilintide + semaglutide) led to ≥20% weight loss in 60% of participants and ≥30% loss in 23%; 88% of those with prediabetes returned to normoglycemia. Novo Nordisk FDA filing decision expected late 2026. (Applied Clinical Trials Online, 2026-07-16)

regulatory: TB-500 is on the July 23, 2026 FDA PCAC agenda alongside BPC-157 for potential 503A compounding eligibility review. The meeting follows removal of TB-500 from Category 2 restrictions effective April 23, 2026, after original nominators withdrew their safety-concern submissions. (FDA.gov, 2026-07-16)

trial_dose: TRIUMPH-1 Phase 3 results (NCT05929066) confirmed 28.3% mean body-weight reduction at 80 weeks with retatrutide 12 mg vs 2.2% placebo in 2,339 participants with obesity. Eli Lilly on track for NDA filing Q4 2026; FDA approval not expected before late 2027. (retaweightloss.com, 2026-07-09)

regulatory: FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 on July 23, 2026 for Section 503A compounding eligibility. The review determines whether bulk BPC-157 can be legally compounded for patients with a prescription — not whether the peptide is FDA-approved. No human trial data supports the compound's current restricted Category 2 classification. (peptideprices.net, 2026-06-03)

trial_dose: A new ClinicalTrials.gov posting (NCT07527195, submitted April 2026) launched a Novo Nordisk study examining how CagriSema, cagrilintide alone, and semaglutide alone affect muscle health during weight loss in adults with overweight and prediabetes. Estimated completion June 2028. Addresses lean-mass concerns raised by higher-dose incretin therapy. (ClinicalTrials.gov, 2026-04-14)

regulatory: TB-500 is also on the July 23, 2026 FDA PCAC agenda alongside BPC-157, KPV, and MOTS-C. The committee will assess 503A compounding eligibility; a favorable vote would allow licensed pharmacies to prepare it per prescription. Reviewers have noted TB-500 has essentially no published human trial data. (peptideprices.net, 2026-06-03)

evidence: A PMC review (2026) notes that oral semaglutide 25 mg achieved 13.6–16.6% weight loss in phase 3 (NCT05564117), comparable to injectable, while higher-dose incretin regimens drive lean-mass losses up to ≥40% of total weight reduction — flagging proactive sarcopenia screening as a clinical priority. (PMC/AJMC, 2026-07)

regulatory: TB-500 is among the peptides up for PCAC review on July 23–24, 2026. Substances were provisionally removed from FDA Category 2 effective April 23, 2026, pending the committee's formal assessment on 503A compounding eligibility. Committee decision does not constitute FDA drug approval. (Pharmacy Times, 2026-07-14)

trial_dose: TRIUMPH Phase 3 program design paper (Giblin et al., Diabetes Obesity & Metabolism, 2026) confirmed: TRIUMPH-1 and TRANSCEND-T2D-1 data show 28.3–28.7% weight loss and –2.0% HbA1c respectively. NDA submission anticipated Q4 2026; TRIUMPH-2 and TRIUMPH-3 readouts pending. (Diabetes, Obesity and Metabolism, 2026)

regulatory: GHK-Cu is listed among ~14 peptides expected to transition from FDA Category 2 back to Category 1 status, with formal PCAC review scheduled July 23–24, 2026. If cleared, licensed 503A compounding pharmacies could legally prepare it under prescription. No formal rule published yet. (BioStrata Research, 2026-06-~)

regulatory: FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to formally review 12 peptides—including BPC-157—for addition to the 503A Bulks List. Public comment docket (FDA-2025-N-6895) closes July 22. Outcome will determine whether licensed 503A pharmacies may legally compound it. No approval decision expected from this meeting. (RAPS, 2026-04-17)

regulatory: Emideltide (DSIP), Semax, and Epitalon are slated for the July 24, 2026 session of the same PCAC meeting. Indications under review include insomnia and cerebral ischemia. A second PCAC meeting before Feb 2027 will cover GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF. (FDA Law Blog / RAPS, 2026-04-17)

regulatory: FDA's Pharmacy Compounding Advisory Committee meets July 23, 2026 — 10 days away — to vote on BPC-157's eligibility for the 503A Bulk Drug Substances List. A positive recommendation would allow licensed compounding pharmacies to legally produce it again after its 2023 Category 2 restriction. Decision is advisory, not final approval. (FDA.gov / RAPS, 2026-04-17)

regulatory: TB-500 is also on the July 23, 2026 PCAC docket alongside BPC-157, KPV, and MOTS-C. The committee will assess whether it meets 503A compounding eligibility criteria. FDA removed it from Category 2 effective April 23, 2026, lessening restrictions ahead of the formal review. (FDA Federal Register notice, 2026-04-16)

trial_dose: Novo Nordisk's NCT07527195 trial, posted April 2026, is actively studying how CagriSema (cagrilintide + semaglutide), cagrilintide alone, and semaglutide alone affect muscle health during weight loss in adults with overweight and prediabetes. Estimated completion June 2028. (ClinicalTrials.gov NCT07527195, 2026-04-14)

regulatory: Eli Lilly remains on track to file an NDA for retatrutide (triple GIP/GLP-1/glucagon agonist) in Q4 2026 following positive TRIUMPH-1 and TRANSCEND-T2D-1 Phase 3 readouts. FDA review is projected to take 10–12 months, pointing to approval around late 2027 and commercial launch Q1–Q2 2028. (retaweightloss.com, 2026-07-07)

regulatory: Emideltide (DSIP) is scheduled for FDA PCAC 503A eligibility review on July 24, 2026 — the second day of the two-day advisory committee meeting — alongside Semax and Epitalon. The committee's recommendations will inform whether compounding pharmacies may legally dispense the peptide under 503A. (Amanecia Health / PCAC agenda, 2026-07-12)

regulatory: FDA's Pharmacy Compounding Advisory Committee (PCAC) is formally convening July 23–24, 2026 to evaluate BPC-157 for Section 503A bulk drug substance eligibility. A positive recommendation would create the first clear legal U.S. compounding pathway; a negative one could close regulated access entirely. PCAC issues recommendations, not final decisions. (Amanecia Health / PCAC agenda, 2026-07-12)

regulatory: TB-500 (Thymosin Beta-4 fragment) is on the July 23, 2026 PCAC agenda alongside BPC-157, KPV, and MOTS-C for 503A compounding eligibility review. Previously held in FDA Category 2 (no compounding permitted) since Sept 2023, it was removed from Category 2 effective April 23, 2026 pending this formal committee evaluation. (Amanecia Health / PCAC agenda, 2026-07-12)

evidence: Survodutide (GLP-1/glucagon dual agonist) Phase 3 SYNCHRONIZE-1 trial, reported April 2026 and presented at ADA June 2026, showed up to 16.6% body weight loss at 76 weeks with substantial reductions in visceral and liver fat in adults with obesity without T2D. LIVERAGE MASH readouts are expected later in 2026. (Life Science Daily News, 2026-06-20)

regulatory: Novo Nordisk's NDA for once-weekly CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) submitted December 18, 2025 remains under active FDA review, with a decision anticipated by late 2026. Phase 3 REDEFINE 1 showed 20.4% mean weight loss at 68 weeks vs. 3.0% placebo. If approved, it would be the first GLP-1/amylin combination injection. (The RX Index, 2026-04-25)

regulatory: TB-500 (Thymosin Beta-4 fragment) is on the July 23, 2026 PCAC agenda alongside BPC-157, KPV, and MOTS-c. The committee will assess whether it qualifies for 503A compounding eligibility after being placed in FDA Category 2 (significant safety concerns) in September 2023. Inclusion would restore licensed pharmacy access under physician prescription. (Amanecia Health, 2026-07-03)

regulatory: FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026, to evaluate BPC-157 for inclusion on the Section 503A Bulk Drug Substances List. A positive recommendation would create a legal compounding pathway for the first time; a negative one could end regulated access. PCAC votes are advisory — FDA issues a final rule typically 6–18 months later. Public docket FDA-2025-N-6895 closes July 22. (HighPeptides, 2026-04-27)

regulatory: FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23, 2026 to review BPC-157 (alongside KPV, TB-500, MOTS-C) for inclusion on the Section 503A Bulk Drug Substances List. Public comment docket FDA-2026-N-2979 closed July 22. A PCAC recommendation is non-binding; formal rulemaking still required before compounding is legally permitted. (FDA.gov, 2026-07-10)

regulatory: TB-500 is on the July 23, 2026 PCAC agenda for 503A compounding eligibility review, alongside BPC-157, KPV, and MOTS-C. The peptide was removed from FDA Category 2 (significant safety concerns) effective April 23, 2026 after its original nomination was withdrawn. PCAC review is a procedural step; 503A listing still requires notice-and-comment rulemaking. (FDA.gov, 2026-07-10)

regulatory: Semax is scheduled for PCAC review on July 24, 2026 for potential Section 503A compounding eligibility, alongside DSIP (emideltide) and epitalon. It was removed from FDA Category 2 in April 2026. A favorable committee recommendation would still require formal FDA rulemaking before licensed compounding pharmacies could legally prepare it. (FDA.gov, 2026-07-10)

regulatory: Eli Lilly remains on track for an NDA filing in Q4 2026 following TRIUMPH-1 and TRANSCEND-T2D-1 confirmations, with FDA review expected to take 10–12 months and market launch projected Q1–Q2 2028. Phase 3 TRIUMPH program (NCT05929066 et al.) has enrolled 5,800+ participants. Retatrutide is not yet FDA-approved. (retaweightloss.com, 2026-07-07)

evidence: At ADA 2026 Scientific Sessions, Phase 3 results for survodutide (dual GLP-1/glucagon agonist) in obesity and in obesity+MASLD were presented, with simultaneous publications in NEJM and Nature respectively — marking the first Phase 3 readout for a GLP-1/glucagon dual agonist. (Docwire News / ADA 2026, 2026-07-06)

regulatory: FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled July 23–24, 2026 to review seven peptides for 503A bulk compounding eligibility, including BPC-157, KPV, and TB-500. No approval conferred; outcome will determine legal compounding status. (joinfound.com / FDA PCAC, 2026-07-09)

sourcing: At ADA 2026, Dr. Lee Kaplan flagged growing patient access to unverified compounded or illicit retatrutide. The drug remains investigational-only; Phase 3 TRIUMPH-2 and TRIUMPH-3 readouts are the next milestones before any NDA filing. (Docwire News / ADA 2026, 2026-07-06)

regulatory: Novo Nordisk's CagriSema NDA (cagrilintide 2.4mg + semaglutide 2.4mg), filed Dec 2025, remains under FDA review with Q4 2026–Q1 2027 approval expected. REDEFINE 1 showed 20.4% mean weight loss at 68 wks vs 3.0% placebo. Higher-dose (7.2mg cagrilintide) trials are planned for late 2026. (BiopharmaPEG / retaweightloss.com, 2026-07-07)

regulatory: FDA Pharmacy Compounding Advisory Committee (PCAC) scheduled July 23, 2026 to review BPC-157 for 503A bulk drug substance compounding eligibility. Decision would affect legal compounding access but does not constitute FDA drug approval. TB-500, KPV, and MOTS-C share the same July 23 agenda day. (Amanecia Health / FDA Federal Register notice, 2026-04-16)

regulatory: TB-500 joins BPC-157, KPV, and MOTS-C on the FDA PCAC July 23, 2026 agenda for 503A compounding eligibility review. Separately, FDA removed 12 peptides from its Category 2 restricted list effective April 23, 2026, easing prior compounding restrictions. Neither action equals FDA drug approval. (Amanecia Health / FDA Federal Register notice, 2026-04-16)

regulatory: CagriSema (cagrilintide + semaglutide), filed with FDA by Novo Nordisk, has an FDA response expected sometime in 2026. Phase 3 REDEFINE 1 showed 22.7% weight loss. GI side-effect profile was consistent with each component individually, per available Phase 3 data. (GoodRx GLP-1 Trends, 2026-07-01; PeptideIQ, 2026-04-30)

trial_dose: Eli Lilly's TRIUMPH-1 Ph3 readout (May 21, 2026) confirmed 28.3% avg weight loss in 2,339 general obesity patients. TRIUMPH-2 (obesity+T2D) and TRIUMPH-3 (obesity+CVD) results still pending 2026. NDA filing targeted Q4 2026; FDA approval projected late 2027. (retaweightloss.com status update, 2026-07-07)

evidence: Eli Lilly announced positive TRIUMPH-1 Phase 3 topline results (May 21, 2026): 12mg dose produced 28.3% avg weight loss at 80 weeks in 2,339 adults with obesity. 45.3% lost ≥30% bodyweight — outcomes previously seen only with bariatric surgery. A 104-week extension subgroup (BMI ≥35) showed 30.3% loss. FDA submission expected late 2026/2027. (retaweightloss.com, 2026-07-01)

regulatory: Novo Nordisk's NDA for CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) submitted Dec 2025 is under active FDA review in 2026, supported by REDEFINE 1 Phase 3 data showing 20.4% avg weight loss at 68 weeks vs 3.0% placebo. 91.9% of CagriSema patients lost ≥5% bodyweight. (biochempeg.com, 2026-01-09)

regulatory: FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 (along with TB-500, thymosin-alpha-1, cjc-1295, ipamorelin, and epitalon) for section 503A compounding eligibility on July 23-24, 2026. This follows the April 23 removal of 12 peptides from the Category 2 restricted list. Review outcome does not constitute FDA drug approval. (meto.co / amaneciahealth.com, 2026-04-28)

regulatory: TB-500 is among seven peptides up for FDA Pharmacy Compounding Advisory Committee review on July 23-24, 2026 for 503A compounding eligibility. Separately, it was not among the 12 peptides removed from the Category 2 list on April 23, 2026. Committee review could restore lawful compounding access if eligibility is confirmed. (amaneciahealth.com, 2026-04-28)

regulatory: TB-500 is among seven peptides on the FDA PCAC July 23, 2026 agenda for 503A compounding eligibility review. It was previously removed from the Category 2 restricted list (effective April 23, 2026), easing pharmacy compounding restrictions ahead of the formal advisory vote. (SSRP Institute, 2026-04-15)

regulatory: CagriSema (cagrilintide + semaglutide) FDA response expected in 2026 per Novo Nordisk filing; a completed Phase 3 ClinicalTrials.gov study (NCT06065540) examining blood sugar and weight vs. semaglutide alone posted final data January 2026. Novo Nordisk filed for FDA approval of CagriSema as the first once-weekly GLP-1/amylin combo. (GoodRx, 2026-07-01)

evidence: Phase 3 TRIUMPH-1 topline results confirmed 28.3% avg weight loss at 12 mg over 80 weeks (2,339 pts); Eli Lilly on track for NDA filing Q4 2026. Highest-dose participants with severe obesity reached ~30% weight loss. NDA filing Q4 2026, FDA review 2027, launch projected early 2028. (Pharmaceutical Journal, 2026-05-22)

regulatory: FDA's Pharmacy Compounding Advisory Committee confirmed July 23, 2026 agenda includes BPC-157 for 503A Bulks List eligibility review — following its removal from the Category 2 restricted compounding list effective April 23, 2026. Meeting determines compounding eligibility only, not drug approval. (Amanecia Health / FDA Federal Register, 2026-04-16)

evidence: Phase 3 TRIUMPH-1 (NCT05929066, n=2,339, 80 wks) confirmed 28.3–30.3% avg weight loss at 12 mg, per topline results published May 21, 2026. Eli Lilly on track for NDA filing Q4 2026; FDA review expected to take 10–12 months. (Pharmaceutical Journal / AJMC, 2026-05-22)

regulatory: FDA's Pharmacy Compounding Advisory Committee (PCAC) formally scheduled to review BPC-157 for 503A Bulks List eligibility on July 23, 2026 — the day after today's date. Outcome will determine whether compounding pharmacies can legally produce it under section 503A. Not an approval proceeding. (Amanecia Health / Olympia Pharmacy, 2026-04-16)